Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in type 2 low asthma in obese and non-obese adults
NL-OMON25171Not yet recruiting
- Sponsor
- Unknown
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of tezepelumab in asthma and Th2 asthma (Th2), sponsored by Unknown. Primary endpoints: Mechanisms and downstream effects of tezepelumab in type 2 low asthma and Identification of type 2 low biomarkers. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
03
Conditions
asthmaTh2 asthma (Th2)
Beyond the preview
Go deeper on NL-OMON25171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25171.